Skip to content
thestock.space

HALEOS LABS (HALEOSLABS) had a P/E of 26.8× on 6 Nov 2026, below the industry P/E of 49.1×, and the shares are 21% below their 52-week high. It earns ROCE of 11% and ROE of 8.4%, and sales and net profit grew 0.3% and 15% a year over 3 years. Its dividend yield is 0.1%, and debt is 0.48× equity. It is a small-cap company with a market cap of ₹423 Cr, ranked 13th of 20 Biotechnology companies by market cap; the shares rose 19% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹1,352.50
Day high
₹1,410.10
Day low
₹1,352.50
Prev. close
₹1,409.80
Volume
1.1K

Health check

2 good · 1 fair · 3 to check
  • ReturnsAhead

    +19.4% over a year, better than 6 of 7 peers.

  • Price tagCheaper

    P/E 26.8 vs industry 49.1.

  • GrowthSlow

    Sales +0.3%, profit +14.7% a year over 3 years.

  • ProfitabilityWeak

    ROCE 10.5% vs peer median 16.7%.

  • Balance sheetFair

    Debt 0.48× equity, interest covered 5.1×, Piotroski 4 of 9.

  • Red flags2 to check

    Quarterly profit down 36.3% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Biotechnology

19 listed peers. Screen the industry

Small cap

₹423 Cr, #13 of 20 in its industry by size.

Defensive

Beta 0.35 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹324 Cr · profit ₹16 Cr
Market cap
₹423 Cr
Small cap
P/E
26.8
Industry 49.1
Price to book
1.98
Peers 4.68
Dividend yield
0.11%
ROE
8.4%
Peers 14.3%
ROCE
10.5%
Peers 16.7%
Debt to equity
0.48
Debt ₹111 Cr
EPS (TTM)
₹52.27
Face value ₹10
OPM (TTM)
12.6%
Net margin 4.9%
Sales growth
−11.6%
Latest quarter vs a year ago
Profit growth
−36.3%
Latest quarter vs a year ago
Price to sales
1.30
EV/EBITDA 13.0

Strengths and risks

Strengths

  • P/E of 26.8 against an industry P/E of 49.1.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 36.3% on a year ago.
  • Quarterly sales down 11.6% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About HALEOS LABS

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and…

Headquarters
Hyderabad
Employees
611
Sector
Healthcare
ISIN
INE320X01016
Website
haleoslabs.com

Price range

52 weeks

₹1,091.10₹1,774.00

Today

₹1,352.50₹1,410.10
Avg volume (3M)
997
1-year return
plus 19.4%
From 52-week high
minus 21.1%

Peers · Biotechnology

Compare with peersScreen the whole industry
Company
BIOCONBiocon365.10plus 0.86%59,794122.51.732.8%1.0%19.4%15.3%−5.9%0.14%minus 4.9%
ANTHEMAnthem Biosciences915.55plus 0.22%51,59484.615.7426.8%20.4%41.4%26.2%15.4%0.22%plus 30.1%
ONESOURCEOnesource Specialty Pharma1,599.80plus 1.13%18,346–3.100.3%0.0%23.5%232.3%–0.00%minus 13.7%
CONCORDBIOConcord Biotech632.60minus 5.96%13,23647.46.4816.7%14.3%34.5%8.0%2.8%0.60%minus 7.5%
BLUEJETBlue Jet Healthcare553.80minus 3.91%9,60734.54.5224.0%19.9%31.4%9.4%15.7%0.22%minus 5.0%
SUPRIYASupriya Lifescience695.80minus 19.99%5,60028.24.6822.3%19.1%21.4%21.2%32.5%0.14%plus 9.2%
ZOTAZota Health Care1,231.10plus 1.01%4,264–6.82−7.3%−24.1%0.1%56.7%–0.08%minus 21.9%
HALEOSLABSHALEOS LABS1,398.80minus 0.78%42326.81.9810.5%8.4%12.6%0.3%14.7%0.11%plus 19.4%
Median of 7 peers–0.22%13,23647.44.6816.7%14.3%23.5%21.2%15.4%0.14%−5.0%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
82.581.494.875.172.9
70.867.880.77163.8
11.713.6144.29.1
14.2%16.7%14.8%5.5%12.5%
10.40.220.5
1.91.61.51.41.9
3.83.93.93.84.2
78.58.80.93.4
37.6%24.3%24.3%62.0%46.5%
4.26.16.60.42.6
13.7520.1921.891.448.75

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+0.3%
Profit CAGR 3Y
+14.7%
EPS CAGR 3Y
+14.7%
ROE
8.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
313300337316
–minus 4.2%+12.4%minus 6.3%
284268292270
28.831.245.145.7
9.2%10.4%13.4%14.5%
2.63.54.52
6.4108.56.1
10.814.91515.5
2.4−00−0.9
16.69.826.225.2
31.4%35.7%28.5%29.4%
11.59.120.117.3
–minus 20.7%+121.2%minus 13.9%
37.9230.0866.5157.26

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3333
166174194211
10010186.4111
126114107130
395391390454
233232236288
4.38.74.320.1
0000
3.60.60.51.2
154150149145
395391390454

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
14.724.334.137.2
−31.3−18.5−15−57.9
16.9−6.6−19.121.4
0.3−0.7−0.10.7
−48.6−20.9−15.3−57.9
−33.93.418.7−20.6
−0.5−0.5−0.5−0.5

Shareholding pattern

Source: NSE filings
72.1%
promoters
  • Promoters72.11%
  • Public27.89%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202672.11%27.89%0.00
30 Jun 202672.11%27.89%0.00
31 Mar 202672.11%27.89%plus 0.31
31 Dec 202571.80%28.20%plus 0.39
30 Sep 202571.41%28.59%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you